New pneumonia vaccine shows promise in early trial
NCT ID NCT05815264
First seen Jan 08, 2026 · Last updated May 15, 2026 · Updated 17 times
Summary
This study tested a new 23-valent pneumococcal polysaccharide vaccine to see if it is safe and triggers an immune response. 144 healthy volunteers aged 2 and older received one dose of either the experimental vaccine or a control vaccine. Researchers monitored side effects for up to 6 months and measured antibody levels before and 28 days after vaccination.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PNEUMONIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Qi County Center for Disease Control and Prevention
Hebi, Henan, China
Conditions
Explore the condition pages connected to this study.